Compare Hims and Hers Health Inc (HIMS) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Hims and Hers Health Inc trades at $27 (market cap $6.47B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Hims and Hers Health Inc is far larger — about 6.6× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| HIMS | MRVI | |
|---|---|---|
Market Cap | $6.47B | $977.37M |
Volume | 10,989,212 | 2,742,564 |
Sector | Health | Health |
52-Week High | $62.76 | $9.00 |
52-Week Low | $14.52 | $2.83 |
Typical Hold Time | 21 Days | 0 Days |
Enterprise Value | $7.17B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health (HIMS) trades at $29.71, down 3.04% on the day, amid a securities class action lawsuit. Technical indicators show a bullish trend, with support near $29 and resistance at $32. Fundamentally, the company reported $2.35B in 2025 revenue but swung to a net loss of -$142M in 2026, with a negative net margin of -5.51%. Valuation ratios are elevated, with a P/E of 57.14 and EV/EBITDA of 205.86. Analyst consensus is a 'Hold' with a $32.17 price target, while recent news is dominated by legal actions.
The outlook for HIMS is clouded by legal overhangs and profitability challenges despite top-line growth. Investment opportunity hinges on resolving litigation and returning to profitability, but risks include regulatory scrutiny and execution missteps. The stock's high valuation multiples require strong future earnings to justify, making it speculative in the near term.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
